Abstract
Background: There is a growing body of pre-clinical evidence suggesting that lithium (Li) may protect neurons from a range of neurotoxic insults, hence the term neuroprotective effects. Does Li have similar effects also in human subjects? Methods: We reviewed the neuroimaging literature investigating the association between Li treatment and brain structure. Results: There is level I evidence for positive association between Li treatment and brain grey matter volume, which is one of the most replicated neuroimaging findings. It has been reported in the majority of cross sectional studies, all 8 prospective studies, including a randomized controlled trial as well as in 2 meta-analyses and one mega-analysis. The association between Li treatment and grey matter volume occurs regardless of mood state, diagnostic subtype, presence or absence of concomitant medications. It was documented in multiple brain regions, including hippocampus, amygdala, anterior cingulate, subgenual cingulate, inferior frontal gyrus, postcentral gyrus, habenula. Conclusion: Although some methodological and clinical issues complicate the interpretation of findings, there is robust and highly replicated level 1 evidence for positive association between Li treatment and grey matter volumes. These "neuroprotective" effects of Li have been shown even in healthy subjects and appear independent of prophylactic treatment response. Consequently, Li might help maintain brain health even in patients without bipolar disorders and could possibly demonstrate diseasemodifying properties in neurodegenerative disorders.
Keywords: Amygdala, cerebral cortex, hippocampus, lithium, magnetic resonance imaging, neuroprotection, neurodegeneration.
Current Alzheimer Research
Title:Neuroprotective Effects of Lithium in Human Brain? Food for Thought
Volume: 13 Issue: 8
Author(s): Tomas Hajek and Michael W. Weiner
Affiliation:
Keywords: Amygdala, cerebral cortex, hippocampus, lithium, magnetic resonance imaging, neuroprotection, neurodegeneration.
Abstract: Background: There is a growing body of pre-clinical evidence suggesting that lithium (Li) may protect neurons from a range of neurotoxic insults, hence the term neuroprotective effects. Does Li have similar effects also in human subjects? Methods: We reviewed the neuroimaging literature investigating the association between Li treatment and brain structure. Results: There is level I evidence for positive association between Li treatment and brain grey matter volume, which is one of the most replicated neuroimaging findings. It has been reported in the majority of cross sectional studies, all 8 prospective studies, including a randomized controlled trial as well as in 2 meta-analyses and one mega-analysis. The association between Li treatment and grey matter volume occurs regardless of mood state, diagnostic subtype, presence or absence of concomitant medications. It was documented in multiple brain regions, including hippocampus, amygdala, anterior cingulate, subgenual cingulate, inferior frontal gyrus, postcentral gyrus, habenula. Conclusion: Although some methodological and clinical issues complicate the interpretation of findings, there is robust and highly replicated level 1 evidence for positive association between Li treatment and grey matter volumes. These "neuroprotective" effects of Li have been shown even in healthy subjects and appear independent of prophylactic treatment response. Consequently, Li might help maintain brain health even in patients without bipolar disorders and could possibly demonstrate diseasemodifying properties in neurodegenerative disorders.
Export Options
About this article
Cite this article as:
Hajek Tomas and W. Weiner Michael, Neuroprotective Effects of Lithium in Human Brain? Food for Thought, Current Alzheimer Research 2016; 13 (8) . https://dx.doi.org/10.2174/1567205013666160219112712
DOI https://dx.doi.org/10.2174/1567205013666160219112712 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Involvement of Advanced Glycation End-products (AGEs) in Alzheimers Disease
Current Alzheimer Research Astrocytes and Gliotransmitters: New Players in the Treatment of Major Depression?
Current Drug Targets Implications of Parkinson’s Disease Pathophysiology for the Development of Cell Replacement Strategies and Drug Discovery in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Drugs with Estrogen-like Potency and Brain Activity Potential Therapeutic Application for the CNS
Current Pharmaceutical Design Inhibition of Disulfide Reductases as a Therapeutic Strategy
Current Enzyme Inhibition Nuclear Imaging of Inflammation in Neurologic and Psychiatric Disorders
Current Clinical Pharmacology Multivalent & Multifunctional Ligands to β-Amyloid
Current Pharmaceutical Design Effects of Proteoglycans on Oxidative/Nitrative Stress
Current Organic Chemistry Disease Modifying Approaches for Alzheimers Pathology
Current Pharmaceutical Design Conference Report: 12<sup>th</sup> International Congress on Neuroprotective Agents (ICNA), Charlottesville, VA, USA September 28, 2014-Ocobert 01, 2014
CNS & Neurological Disorders - Drug Targets Autism: Pathophysiology and Promising Herbal Remedies
Current Pharmaceutical Design Novel Strategies and Tools for Enhanced Sensitivity in Routine Biomolecule Analytics
Current Pharmaceutical Analysis NRF2-Dependent Glutamate-L-Cysteine Ligase Catalytic Subunit Expression Mediates Insulin Protection Against Hyperglycemia-Induced Brain Endothelial Cell Apoptosis
Current Neurovascular Research Pharmacoproteomics Applications for Drug Target Discovery in CNS Disorders
Current Pharmacogenomics and Personalized Medicine Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration
Current Neuropharmacology Getting to Know the Cast - Cellular Interactions and Signaling at the Neurovascular Unit
Current Pharmaceutical Design Design of NAALADase Inhibitors A Novel Neuroprotective Strategy
Current Medicinal Chemistry Cholesterol, Alzheimers Disease, Prion Disorders: A menage a trois?
Current Drug Targets The Nearest-Neighbor Effect on Random-Coil NMR Chemical Shifts Demonstrated Using a Low-Complexity Amino-Acid Sequence
Protein & Peptide Letters Recents Patents for Isolating, Delivering and Tracking Adult Stem Cells in Regenerative Medicine
Recent Patents on Drug Delivery & Formulation